Asia
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Companies from across the globe announce updates to their business and pipeline.
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Sumitovant will run as a wholly owned subsidiary of Sumitomo Dainippon Pharma.
The Shenzhen Nanshan District People’s Court sentenced He today to three years in prison and a fine of 3 million yuan ($430,000 U.S.). Two other medical researchers, Zhang Renli and Qin Jinzhou, worked with He and were also sentenced.
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
Cerecin, an innovative biopharmaceutical company focused on brain health, announced that Joseph S. Zakrzewski has joined the Company’s Board of Directors as Chairman.
This year marked yet another series of interesting, exciting and occasionally puzzling stories coming out of the biopharma industry. Our breaking news writers, Alex Keown and Mark Terry, picked their top 10 stories of the year.
The clinical trials the approval is based on suggested the drug was effective for treating primary insomnia but may also be effective for insomnia associated with other diseases, such as depression.
Specifically, it was approved for adults with unresectable or metastatic HER2-positive breast cancer who have had two or more previous anti-HER2-based treatments in the metastatic setting.
PRESS RELEASES